Year: 2021

Simcyp Simulator has been used to inform more than 250 label claims for 85+ novel drugs PRINCETON, N.J., Dec. 02, 2021 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Simulator Version 21, which updates the Company’s population-based modeling and simulation platform. The Simcyp Simulator is used throughout the drug development process to evaluate new drug formulations, determine first-in-human dosing, optimize clinical study design and predict drug-drug interactions. Certara’s Simcyp physiologically-based pharmacokinetic (PBPK) Simulator models describe the behavior of drugs in different body tissues and include genetic, physiological and epidemiological databases that facilitate simulations in virtual populations. The Simcyp Simulator has been used to inform...

TORTOLA, British Virgin Islands, Dec. 02, 2021 (GLOBE NEWSWIRE) — Orca Energy Group Inc. (“Orca” or the “Company” and includes its subsidiaries and affiliates) (TSX-V: ORC.A, ORC.B) today announces an operations update and guidance for 2022. All amounts are in United States dollars (“$”) unless otherwise stated. Jay Lyons, Chief Executive Officer, commented: “Despite challenges associated with global supply chains and other COVID-19 related issues, we are very pleased to announce good progress on our 2021 work programs, a significant $50 million capital program and further guidance for 2022.   These plans are consistent with Orca’s 20 year track record of proactive investment and field development to ensure sustainable gas supply to the United Republic of Tanzania. Subject to Government approvals, the proposed plan will enable...

WOBURN, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) — Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing a range of product candidates derived from its oncolytic immuno-gene therapy platform, today announced the appointment of Christy Oliger to the Company’s Board of Directors effective December 1, 2021. “We are delighted to welcome Christy to Replimune’s Board of Directors,” said Philip Astley-Sparke, Chief Executive Officer of Replimune. “Christy brings nearly 30 years of commercial and business experience in the pharmaceutical and biotechnology industry foremostly in oncology. We look forward to working with Christy and believe her guidance and input will strengthen our board as we advance our leading pipeline of oncolytic immunotherapies to market.” Previously Ms. Oliger was Senior Vice President of the Oncology...

NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) — Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that President and CEO Howard Federoff, M.D., Ph.D. is scheduled to present at the following virtual conferences: Benzinga Global Small Cap Conference: December 8 – 9, 2021Dr. Federoff will deliver his corporate presentation on Wednesday, December 8 at 4:40 PM EST.Management will be available for one-on-one meetings to be held throughout the conference.Investors can register here:https://www.benzinga.com/events/small-cap/december-2021-global/MedInvest Oncology Investor Conference: December 7 – 10, 2021Dr. Federoff will...

NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) — SeatGeek, the high-growth live event technology platform, today announced that management will host investor meetings on Monday, December 6, 2021 at the Raymond James Virtual Technology Investors Conference. To schedule a one-on-one meeting with SeatGeek, please contact your representative at Raymond James. As previously announced on October 13, 2021, SeatGeek and RedBall Acquisition Corp. (“RedBall”) (NYSE: RBAC), a publicly traded special purpose acquisition company sponsored by RedBall SponsorCo LP, an affiliate of RedBird Capital Partners, entered into a definitive business combination agreement. The boards of directors of both RedBall and SeatGeek have unanimously approved the transaction. It is expected to close in the first quarter of 2022, subject to customary closing conditions,...

Grant of $400,000 to help expand sickle cell disease real-world data gathering in the U.S. WASHINGTON and SOUTH SAN FRANCISCO, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) — The ASH Research Collaborative (ASH RC), a non-profit organization established in 2018 by the American Society of Hematology (ASH), and Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that GBT will provide a grant of $400,000 to the ASH RC in support of the ASH RC Data Hub Sickle Cell Disease (SCD) program. With the Data Hub SCD program, the ASH RC seeks to advance research and outcomes for people living with SCD by expanding its current data collection of real-world, research-grade data to include more than half of people living with SCD in the United States. “We have a shared mission with GBT to help transform the treatment of sickle cell disease,”...

VANCOUVER, British Columbia, Dec. 02, 2021 (GLOBE NEWSWIRE) — BIGG Digital Assets Inc. (“BIGG” or the “Company”)(CSE: BIGG; OTCQX: BBKCF; WKN: A2PS9W), owner of Netcoins (Netcoins.ca) (“Netcoins”), the online cryptocurrency brokerage that makes it easy for Canadians to buy, sell, and understand cryptocurrency, and owner of Blockchain Intelligence Group (blockchaingroup.io) (“BIG”), a leading developer of blockchain technology search, risk-scoring and data analytics solutions, is pleased to announce its strategic investment of CAD $100,000 in TerraZero Technologies Inc’s recent private financing round. TerraZero Technologies’ vision is to Develop, Acquire, and Finance the Metaverse’s most promising companies, entrepreneurs, and developers. We build solutions to further enhance the Metaverse usability for greater community...

TORONTO, Dec. 02, 2021 (GLOBE NEWSWIRE) — Celestica Inc. (NYSE: CLS) (TSX: CLS), a leader in design, manufacturing and supply chain solutions for the world’s most innovative companies, today announced that the Toronto Stock Exchange (the “TSX”) has accepted the Company’s notice to launch a Normal Course Issuer Bid (the “Bid”). Under the Bid, the Company may, and intends to, repurchase on the open market, at its discretion during the period commencing on December 6, 2021 and ending on the earlier of December 5, 2022 and the completion of purchases under the Bid, up to 8,987,310 subordinate voting shares, representing approximately 10% of the “public float” of the subordinate voting shares (within the meaning of the rules of the TSX), subject to the normal terms and limitations of such bids. Under the TSX...

Fobi’s hardware and software solutions will now be available on Amazon Business, reaching over five million businesses worldwide VANCOUVER, British Columbia, Dec. 02, 2021 (GLOBE NEWSWIRE) — Fobi AI Inc. Inc. (FOBI:TSXV FOBIF:OTCQB) (the “Company” or “Fobi”), a leader in providing real-time data analytics through artificial intelligence to drive customer activation and engagement, announced it has signed an agreement with Amazon for distribution and fulfillment of Fobi AI’s various hardware products. As part of the agreement, Fobi will also become an Amazon Business Seller which will enable Fobi to gain access to Amazon’s global e-commerce, logistics and fulfillment infrastructure.   By joining Amazon Business, Fobi immediately reaches over 5 million business customers in nine countries: a network that Fobi is very proud to now...